0001725430-26-000002.txt : 20260914 0001725430-26-000002.hdr.sgml : 20260914 20260914112302 ACCESSION NUMBER: 0001725430-26-000002 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: Rule 506(b) provides a "safer harbor" for a private offering FILED AS OF DATE: 20260914 DATE AS OF CHANGE: 20260914 EFFECTIVENESS DATE: 20260914 FILER: COMPANY DATA: COMPANY CONFORMED NAME: INTELLIGENT BIO SOLUTIONS INC. CENTRAL INDEX KEY: 0001725430 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 821512711 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-597341 FILM NUMBER: 261376338 BUSINESS ADDRESS: STREET 1: 135 W 41ST ST, STREET 2: FLOOR 5 CITY: NEW YORK STATE: NY ZIP: 10036 BUSINESS PHONE: 646-790-5756 MAIL ADDRESS: STREET 1: 135 W 41ST ST, STREET 2: FLOOR 5 CITY: NEW YORK STATE: NY ZIP: 10036 FORMER COMPANY: FORMER CONFORMED NAME: GBS Inc. DATE OF NAME CHANGE: 20190919 FORMER COMPANY: FORMER CONFORMED NAME: Glucose Biosensor Systems (Greater China) Holdings, Inc. DATE OF NAME CHANGE: 20171214 D 1 primary_doc.xml X0708 D LIVE 0001725430 INTELLIGENT BIO SOLUTIONS INC. 135 West 41st Street 5th Floor New York NY NEW YORK 10036 646-790-5756 DELAWARE GBS Inc. Glucose Biosensor Systems (Greater China) Holdings, Inc. Corporation true Harry Simeonidis 135 West 41st Street 5th Floor New York NY NEW YORK 10036 Executive Officer Chief Executive Officer Spiro Sakiris 135 West 41st Street 5th Floor New York NY NEW YORK 10036 Executive Officer Chief Financial Officer Steven Boyages 135 West 41st Street 5th Floor New York NY NEW YORK 10036 Director Director Jonathan Hurd 135 West 41st Street 5th Floor New York NY NEW YORK 10036 Director Director Jason Isenberg 135 West 41st Street 5th Floor New York NY NEW YORK 10036 Director Director Nicola Fraser 135 West 41st Street 5th Floor New York NY NEW YORK 10036 Director Director Other Health Care Decline to Disclose 06b false 2026-08-31 false true true false 0 Ladenburg Thalmann & Co. Inc. 505 None None 640 5th Avenue 4th Floor New York NY NEW YORK 10019 IL ILLINOIS false 4979631 4979631 0 Offering closed September 2, 2026 false 1 399999 0 Ladenburg received $399,999.83 in commission, a $49,999.98 management fee, $60,000 expense reimbursement, and warrants for 101,832 shares of common stock. Ladenburg also receives 9% commission on gross proceeds from Series N-1 and N-2 Warrant exercises. 0 false INTELLIGENT BIO SOLUTIONS INC. /s/ Spiro Sakiris Spiro Sakiris Chief Financial Officer 2026-09-14